FDA is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns
[9/26/2024] FDA is alerting patients, caregivers, and health care professionals that Oxbryta (voxelotor)...
FDA alerts health care professionals and oncology clinical investigators about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer
[9/08/2020] FDA is alerting health care professionals, oncology clinical investigators, and patients...